Phase 2 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to understand and agree to participate by giving informed consent
- People who have been confirmed by pathology testing to have a newly diagnosed Grade IV Glioblastoma Multiforme (a type of brain tumour)
- People who have finished the first 6-week phase of the standard combined chemotherapy and radiation treatment (known as the Stupp protocol) and have not yet started the follow-on maintenance phase
- People who are willing to use effective barrier contraception during treatment and for 2 months after, if there is any possibility of becoming pregnant
- People with a life expectancy of more than 3 months
- People aged between 18 and 74 years
- People with a functional ability score (KPS) of 70 or higher, meaning they are reasonably able to care for themselves (confirm with trial site)
- People who are able to swallow pills and capsules
- People who are able to tolerate oral chemotherapy medications, with no serious allergies or side effects, based on blood tests and clinical assessment
- People whose bone marrow, liver, and kidney function are all within acceptable levels before starting treatment
Who may not be able to join:
- People who have previously received chemotherapy with capecitabine or temozolomide for a different cancer, or who have received similar drugs (continuous infusion 5-FU or DTIC) for any prior malignancy
- People who have received chemotherapy for their current brain tumour diagnosis, other than temozolomide given alongside radiation
- People who have had a severe allergic reaction (such as anaphylaxis) to capecitabine, 5-FU, or temozolomide
- People with a serious medical or psychiatric condition that would prevent them from giving informed consent or receiving treatment (for example, a serious active infection)
- People who have had another cancer in the past 5 years, unless it was fully treated with the intent to cure and the person has been cancer-free for at least one year
- People with a functional ability score (KPS) below 70
- People who are unable to swallow pills and capsules
- People currently receiving any other chemotherapy, active disease treatment, or using devices such as Optune, high-dose vitamin supplements, or any other chemotherapy at the same time
- People taking certain medications such as Coumadin (warfarin) or phenytoin, which can interact with capecitabine
- People with a previously documented history of coronary artery disease (a heart condition) would need to be assessed by a heart specialist before joining, to evaluate their suitability for capecitabine (confirm with trial site)
- People with reduced kidney or liver function
- People with blood clotting disorders
- People who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: John Boockvar, MD, Lenox Hill Hospital-Northwell Health
Phone: 212-434-3900
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-free survival (PFS); Overall Survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.